|Principal Investigator/ Physician||Marcus Tan, MD|
|Contact Email||MCI Clinical Trials|
Protocol Title: "A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma."
Inclusion Criteria: Patient must have measurable disease in the pancreas, patients must have resectable primary tumor based on contract-enhanced CT or MRI of the chest, abdomen, and pelvis; patient must not have received prior surgery, radiation therapy, chemotherapy, targeted therapy or any investigational therapy for pancreatic cancer, must have Zubrod performance status of 0-1.
Clinical Trails.Gov Link: https://clinicaltrials.gov/ct2/show/NCT02562716?term=s1505&rank=1
© 2018 USA Health